164. Oculocutaneous albinism Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 15 Drugs : 54 - (DrugBank : 34) / Drug target genes : 35 - Drug target pathways : 141

Drugs and their primary sponsors and trial info
6-Mercaptopurine   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 2   NCT00514982   United States;
Abatacept   
   Emory University
      2014   Phase 1   NCT01917708   United States;
Adalimumab   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 2   NCT00514982   United States;
Alefacept   
   Emory University
      2010   -   NCT01319851   United States;
Alemtuzumab   
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
Allogeneic Bone Marrow Transplantation   
   Fairview University Medical Center
      2000   -   NCT00006054   United States;
Allogeneic hematopoietic stem cell transplantation   
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
Anti-thymocyte globulin   
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
Anti-thymocyte globulin (ATG)   
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00176865   United States;
Busulfan   
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
Campath 1H   
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00176865   United States;
Corticosteroids   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 2   NCT00514982   United States;
Cyclophosphamide   
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
Cyclosporin A   
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00176865   United States;
Cyclosporine   
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
Erythromycin   
   National Human Genome Research Institute (NHGRI)
      2007   Phase 1/Phase 2   NCT00467831   United States;
Etoposide   
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
Filgrastim   
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
Fludarabine   
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00176865   United States;
Fludarabine phosphate   
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
Infliximab   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 2   NCT00514982   United States;
Intravenous immunoglobulin (IVIG)   
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00176865   United States;
Levodopa/carbidopa   
   University of Wisconsin, Madison
      2012   Phase 2   NCT01663935   United States;
Losartan   
   National Human Genome Research Institute (NHGRI)
      2007   Phase 1/Phase 2   NCT00467831   United States;
Lutein plus Zeaxanthin   
   Johns Hopkins University
      2014   -   NCT02200263   United States;
Melphalan   
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
      2002   Phase 2   NCT00176865   United States;
Mesalamine   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 2   NCT00514982   United States;
Methotrexate   
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
Methylprednisolone   
   Fairview University Medical Center
      2000   -   NCT00006054   United States;
Mycophenolate mofetil   
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00176865   United States;
Myeloablative conditioning regimen   
   Masonic Cancer Center, University of Minnesota
      2000   Phase 2/Phase 3   NCT00176826   United States;
N-Acetylcysteine   
   National Human Genome Research Institute (NHGRI)
      2007   Phase 1/Phase 2   NCT00467831   United States;
Nitisinone   
   National Eye Institute (NEI)
      2013   Phase 1/Phase 2   NCT01838655   United States;
Pirfenidone   
   Jesse Roman
      2019   Phase 2   NCT04193592   Puerto Rico;United States;
   William Gahl, M.D.
      2005   Phase 2   NCT00001596   Puerto Rico;United States;
Pravastatin   
   National Human Genome Research Institute (NHGRI)
      2007   Phase 1/Phase 2   NCT00467831   United States;
Prednisone   
   Fairview University Medical Center
      2000   -   NCT00006054   United States;
Stem Cell Transplant   
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00176865   United States;
      2000   Phase 2/Phase 3   NCT00176826   United States;
Stem Cell Transplantation   
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
Tacrolimus   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 2   NCT00514982   United States;
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan   
   Washington University School of Medicine
      2013   Phase 2   NCT01821781   United States;
Zileuton   
   National Human Genome Research Institute (NHGRI)
      2007   Phase 1/Phase 2   NCT00467831   United States;